# Pamiparib

Source: https://onco.cc/drugs/pamiparib/  
OnCo record `pamiparib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.

## Summary

Pamiparib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by BeiGene, in ovarian cancer. A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Also known as: BGB-290
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral PARP inhibitor
- Mechanism: A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway.

## Sources

- ClinicalTrials.gov: trials of Pamiparib: https://clinicaltrials.gov/search?intr=Pamiparib

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)
- trials: [Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct03519230/)

---
JSON: https://onco.cc/api/v1/entities/pamiparib.json